IDH1 and central nervous system cancer: Patients with a known diagnosis of IDH1-mutant glioma who required surgery for tumor recurrence were randomized to receive vorasidenib (at a dose of either 10 or 50 mg daily), ivosidenib (either 250 mg twice daily or 500 mg daily), or no treatment prior to surgery.